FK16 has been shown to exhibit strong bactericidal activity against ESKAPE organisms (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter spp.) . GF17, a N-glycinated variant of FK16, has also been shown to exhibit anti-cancer, anti-bacterial and anti-viral activities.
Mohammed I, Said DG, Nubile M, Mastropasqua L, Dua HS. Cathelicidin-Derived Synthetic Peptide Improves Therapeutic Potential of Vancomycin Against Pseudomonas aeruginosa. Front Microbiol. 2019 Sep 19;10:2190. doi: 10.3389/fmicb.2019.02190. PMID: 31608030; PMCID: PMC6761703.